Licensing Agreement between Sucampo and Harbin Gloria Pharmaceuticals in China Signed for AMITIZA® (lubiprostone)


Published Date : May 12, 2015

Sucampo Pharmaceuticals, Inc. has entered into a licensed agreement with Harbin Gloria Pharmaceuticals Co., (Gloria) on 11 May, 2015 in the People’s Republic of China. Sucampo Pharmaceuticals, Inc. is a leading global biopharmaceutical company and is headquartered in Bethseda, Maryland. Harbin Gloria Pharmaceuticals Co., Ltd. is a leading healthcare organization based in China.

This agreement grants Gloria the rights to develop and commercialize AMITIZA® (lubiprostone) in China after the product is approved according to regulations, by China Food and Drug Administration.

According to the CEO of Sucampo, the partnership between the two pharmaceutical companies will help in reaching out to a global market. Gloria’s established infrastructure and expertise can provide improved therapy for Chinese patients.

With this agreement Sucampo receives a payment of $1.5 million within a period of two months in installments of $ 1 million and $ 500,000. Sucampo will in addition receive another milestone payment with the occurrence of regulatory or alternative commercial milestone event. Sucampo will be the exclusive supplier of AMITIZA to Gloria and the agreement term is set at 13 years which includes renewal terms. The agreement gives Gloria rights to commercialize and regulatory activities in China.

AMITIZA® (lubiprostone) is indicated in U.S. for treatment of adults with CIC and OIC with chronic and non-cancer pain. Dosage is (24 mcg twice daily). Women over 18 years of age are indicated (8 mcg twice daily) in U.S. for treatment of IBS-C.  In Japan AMITIZA is indicated for treatment of chronic constipation (not caused by organic diseases). AMITIZA is indicated for use in UK and Switzerland. Patients should note important safety information about the drug before considering its use.